Chia-Shi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chia-Shi Wang has a total of 588 co-authors. Here are the top co-authors by number of shared publications:
Larry A. Greenbaum
Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia
11 shared publicationsTarak Srivastava
8 shared publicationsElizabeth Brown
7 shared publicationsFrederick Kaskel
6 shared publicationsKeisha Gibson
6 shared publicationsKevin Meyers
6 shared publications
Latest Publications
- 17 February 2026
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (10) , 1-11
Treatment outcomes and ongoing pediatric trials in steroid-resistant nephrotic syndrome
Despite an increasing number of therapeutic options for pediatric patients with steroid-resistant nephrotic syndrome (SRNS), treatment resistance and risk of progression to kidney failure are still high. Children with monogenic forms of SRNS and resistance to non-steroidal immunosuppressants are at the highest risk. Advances in the understanding of SRNS pathogenesis have enabled the development of novel therapies that target genetic, immunologic, and metabolic mechanisms of disease development and progression. In this review, we summarize select contemporary cohort study findings, novel therapeutic agents and their mechanistic targets, and eight recent and ongoing clinical trials for pediatric patients with SRNS. Graphical abstract A higher-resolution version of the Graphical abstract is available as Supplementary information
- 17 February 2026
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (10) , 1-11
Treatment outcomes and ongoing pediatric trials in steroid-resistant nephrotic syndrome
Despite an increasing number of therapeutic options for pediatric patients with steroid-resistant nephrotic syndrome (SRNS), treatment resistance and risk of progression to kidney failure are still high. Children with monogenic forms of SRNS and resistance to non-steroidal immunosuppressants are at the highest risk. Advances in the understanding of SRNS pathogenesis have enabled the development of novel therapies that target genetic, immunologic, and metabolic mechanisms of disease development and progression. In this review, we summarize select contemporary cohort study findings, novel therapeutic agents and their mechanistic targets, and eight recent and ongoing clinical trials for pediatric patients with SRNS. Graphical abstract A higher-resolution version of the Graphical abstract is available as Supplementary information
- 21 January 2026
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 87 (2) , 141-152
KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children
- 21 January 2026
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 87 (2) , 141-152
KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children
- 15 January 2026
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (6) , 1761-1769
Hyperkalemia in pediatric nephrectomy: a common complication
Background Hyperkalemia following nephrectomies in children is a poorly studied, potentially life-threatening complication. We describe the frequency and risk factors for hyperkalemia in pediatric patients who underwent nephrectomies resulting in an anephric state. Methods This was a single center retrospective cohort study of patients < 21y who underwent nephrectomies resulting in an anephric state. Possible predictors included age, sex, preoperative potassium value, preoperative dialysis modality, preoperative urine output, procedure type, surgical approach, intraoperative lactated Ringer’s (LR), and intraoperative blood. The primary outcome was intraoperative and postoperative day 0 and day 1 hyperkalemia. Hyperkalemia was defined as potassium > 5.1 mEq/L (severe > 5.9) in children ≥ 1y and > 5.5 (severe > 6.1) in children < 1y. Treatments for hyperkalemia were recorded. We examined associations with hyperkalemia using Wilcoxon rank-sum test, Pearson’s Chi-squared test, or Fisher’s exact test. We used Youden’s Index to determine the preoperative potassium cutoff for predicting hyperkalemia. Results Among 46 patients who underwent nephrectomies resulting in an anephric state, 23 (50%) experienced hyperkalemia that was severe in 18 (39%), treated in 21 (46%), and precipitated transfer to the intensive care unit in 5 (11%). In unadjusted analysis, higher preoperative potassium (p < 0.001) and intraoperative LR (p = 0.018) were associated with a higher risk of postoperative hyperkalemia. A preoperative potassium of >3.85 mEq/L was associated with the development of hyperkalemia (p < 0.001). Conclusions Clinically important hyperkalemia is a common complication following nephrectomy that results in an anephric state. Targeting a preoperative potassium < 3.85 mEq/L may decrease intraoperative and postoperative hyperkalemia. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- 15 January 2026
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (6) , 1761-1769
Hyperkalemia in pediatric nephrectomy: a common complication
Background Hyperkalemia following nephrectomies in children is a poorly studied, potentially life-threatening complication. We describe the frequency and risk factors for hyperkalemia in pediatric patients who underwent nephrectomies resulting in an anephric state. Methods This was a single center retrospective cohort study of patients < 21y who underwent nephrectomies resulting in an anephric state. Possible predictors included age, sex, preoperative potassium value, preoperative dialysis modality, preoperative urine output, procedure type, surgical approach, intraoperative lactated Ringer’s (LR), and intraoperative blood. The primary outcome was intraoperative and postoperative day 0 and day 1 hyperkalemia. Hyperkalemia was defined as potassium > 5.1 mEq/L (severe > 5.9) in children ≥ 1y and > 5.5 (severe > 6.1) in children < 1y. Treatments for hyperkalemia were recorded. We examined associations with hyperkalemia using Wilcoxon rank-sum test, Pearson’s Chi-squared test, or Fisher’s exact test. We used Youden’s Index to determine the preoperative potassium cutoff for predicting hyperkalemia. Results Among 46 patients who underwent nephrectomies resulting in an anephric state, 23 (50%) experienced hyperkalemia that was severe in 18 (39%), treated in 21 (46%), and precipitated transfer to the intensive care unit in 5 (11%). In unadjusted analysis, higher preoperative potassium (p < 0.001) and intraoperative LR (p = 0.018) were associated with a higher risk of postoperative hyperkalemia. A preoperative potassium of >3.85 mEq/L was associated with the development of hyperkalemia (p < 0.001). Conclusions Clinically important hyperkalemia is a common complication following nephrectomy that results in an anephric state. Targeting a preoperative potassium < 3.85 mEq/L may decrease intraoperative and postoperative hyperkalemia. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information
- Open Access
- 4 March 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (7) , 1096-1105
Incidence of Leading Causes of Pediatric CKD Using Electronic Health Record-Driven Computable Phenotype
Key Points: We created computable phenotypes to accurately identify cases of pediatric CKD by underlying diagnosis. Combined annual incidence of five leading causes of pediatric CKD was high, 47.07 (95% confidence interval, 45.96 to 48.20) per 100,000 children. Our computable phenotypes have the potential to be broadly implemented to advance epidemiologic research in pediatric CKD. Background: Incidence data on pediatric CKD are incomplete. We developed electronic health record–based algorithms (e-phenotypes) to identify cases and provide incidence estimates of five leading causes of pediatric CKD. Methods: E-phenotypes using common standardized clinical terminology were built and contained utilization, diagnostic, procedural, age, and time-period inclusion and exclusion criteria for autosomal dominant polycystic kidney disease (ADPKD), Alport syndrome (AS), congenital anomalies of the kidney and urinary tract (CAKUT), lupus nephritis (LN), and primary childhood nephrotic syndrome (NS). Cases diagnosed between 2014 and 2023 were identified from a pediatric health care system that is the sole pediatric nephrology provider serving the Atlanta Metropolitan Statistical Area. The performance of the e-phenotypes was tested using a cohort of 1000 pediatric patients. The cases identified were used to estimate incidences using population information from the Georgia Department of Health. Results: The e-phenotypes demonstrated sensitivity ranging from 0.83 to 0.95, specificity 0.96 to 1.00, positive predictive value 0.81 to 1.00, and negative predictive value 0.98 to 1.00. The positive likelihood ratio was >20, and the negative likelihood ratio was n=107), AS (n=31), CAKUT (n=6120), LN (n=161), and NS (n=395) had an annual incidence of 47.07 (95% confidence interval, 45.96 to 48.20) per 100,000 children. Annual incidence per 100,000 children (95% confidence interval) for each condition was ADPKD 0.74 (0.61 to 0.89), AS 0.21 (0.15 to 0.30), CAKUT 42.28 (41.22 to 43.35), LN 1.11 (0.95 to 1.30), and NS 2.73 (2.47 to 3.01). Conclusions: Our incidence estimates suggest that CKD conditions are common among children. The e-phenotypes require validation for use at other institutions but offer opportunities to examine determinants of CKD detection, management, and outcomes.
- 4 March 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (7) , 1096-1105
Open AccessIncidence of Leading Causes of Pediatric CKD Using Electronic Health Record-Driven Computable Phenotype
Key Points: We created computable phenotypes to accurately identify cases of pediatric CKD by underlying diagnosis. Combined annual incidence of five leading causes of pediatric CKD was high, 47.07 (95% confidence interval, 45.96 to 48.20) per 100,000 children. Our computable phenotypes have the potential to be broadly implemented to advance epidemiologic research in pediatric CKD. Background: Incidence data on pediatric CKD are incomplete. We developed electronic health record–based algorithms (e-phenotypes) to identify cases and provide incidence estimates of five leading causes of pediatric CKD. Methods: E-phenotypes using common standardized clinical terminology were built and contained utilization, diagnostic, procedural, age, and time-period inclusion and exclusion criteria for autosomal dominant polycystic kidney disease (ADPKD), Alport syndrome (AS), congenital anomalies of the kidney and urinary tract (CAKUT), lupus nephritis (LN), and primary childhood nephrotic syndrome (NS). Cases diagnosed between 2014 and 2023 were identified from a pediatric health care system that is the sole pediatric nephrology provider serving the Atlanta Metropolitan Statistical Area. The performance of the e-phenotypes was tested using a cohort of 1000 pediatric patients. The cases identified were used to estimate incidences using population information from the Georgia Department of Health. Results: The e-phenotypes demonstrated sensitivity ranging from 0.83 to 0.95, specificity 0.96 to 1.00, positive predictive value 0.81 to 1.00, and negative predictive value 0.98 to 1.00. The positive likelihood ratio was >20, and the negative likelihood ratio was n=107), AS (n=31), CAKUT (n=6120), LN (n=161), and NS (n=395) had an annual incidence of 47.07 (95% confidence interval, 45.96 to 48.20) per 100,000 children. Annual incidence per 100,000 children (95% confidence interval) for each condition was ADPKD 0.74 (0.61 to 0.89), AS 0.21 (0.15 to 0.30), CAKUT 42.28 (41.22 to 43.35), LN 1.11 (0.95 to 1.30), and NS 2.73 (2.47 to 3.01). Conclusions: Our incidence estimates suggest that CKD conditions are common among children. The e-phenotypes require validation for use at other institutions but offer opportunities to examine determinants of CKD detection, management, and outcomes.
- 17 January 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (4) , 555-562
New Index Demonstrates Association between Social Vulnerability, Environmental Burden, and Kidney Failure Risk among Individuals with Glomerular Disease
Key Points: More tools are needed to explore upstream drivers of racial and ethnic disparities in kidney disease outcomes. The Centers for Disease Control and Prevention Environmental Justice Index is a new tool which characterizes cumulative social and environmental burden at the census tract level. This study is the first application of the Environmental Justice Index to understanding glomerular disease outcomes. Background: The Centers for Disease Control and Prevention Environmental Justice Index Social-Environmental Ranking (EJI-SER) combines a Social Vulnerability Module with an Environmental Burden Module to characterize cumulative environmental and social burden at the census tract level. This analysis evaluates the association between EJI-SER and kidney outcomes in patients with glomerular disease (GD). Methods: Cure Glomerulopathy is an observational cohort study of adults and children with biopsy-proven GD. EJI-SER is a percentile ranking by census tract, with a higher score indicating a more severe burden. Associations between EJI-SER and its components with kidney failure (initiation of KRT, transplant, or two eGFRs 25%–50% versus >75%, respectively) and higher eGFR at enrolllment (adjusted mean 90.1 versus 87.1 ml/min per 1.73 m2 for 0%–25% versus >75%, P = 0.08). Conclusions: As captured by EJI-SER, higher environmental and social burdens are associated with lower eGFR and a higher risk of kidney failure in the Cure Glomerulopathy cohort. This first use of the EJI-SER in GD demonstrates the need for additional investigation into social drivers of disparities in GD and policies and resources that address these structural inequities.
- 17 January 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (4) , 555-562
New Index Demonstrates Association between Social Vulnerability, Environmental Burden, and Kidney Failure Risk among Individuals with Glomerular Disease
Key Points: More tools are needed to explore upstream drivers of racial and ethnic disparities in kidney disease outcomes. The Centers for Disease Control and Prevention Environmental Justice Index is a new tool which characterizes cumulative social and environmental burden at the census tract level. This study is the first application of the Environmental Justice Index to understanding glomerular disease outcomes. Background: The Centers for Disease Control and Prevention Environmental Justice Index Social-Environmental Ranking (EJI-SER) combines a Social Vulnerability Module with an Environmental Burden Module to characterize cumulative environmental and social burden at the census tract level. This analysis evaluates the association between EJI-SER and kidney outcomes in patients with glomerular disease (GD). Methods: Cure Glomerulopathy is an observational cohort study of adults and children with biopsy-proven GD. EJI-SER is a percentile ranking by census tract, with a higher score indicating a more severe burden. Associations between EJI-SER and its components with kidney failure (initiation of KRT, transplant, or two eGFRs 25%–50% versus >75%, respectively) and higher eGFR at enrolllment (adjusted mean 90.1 versus 87.1 ml/min per 1.73 m2 for 0%–25% versus >75%, P = 0.08). Conclusions: As captured by EJI-SER, higher environmental and social burdens are associated with lower eGFR and a higher risk of kidney failure in the Cure Glomerulopathy cohort. This first use of the EJI-SER in GD demonstrates the need for additional investigation into social drivers of disparities in GD and policies and resources that address these structural inequities.
- Open Access
- 3 May 2024
- Published by S. Karger AG in Glomerular Diseases
- Vol. 4 (1) , 105-118
Design of a User-Centered Electronic Health Tool for Glomerular Disease Management
Introduction Patients with primary glomerular disease (GN) have unique management needs. We describe the design of a user-centered, patient-facing electronic health (eHealth) tool to support GN management. Methods We surveyed patients and GN expert nephrologists on disease management tasks, educational needs, and barriers and facilitators of eHealth tool use. Results were summarized and presented to patients, nephrologists, engineers, and a behavioral and implementation science expert in stakeholder meetings to jointly design an eHealth tool. Key themes from the meetings are described using rapid qualitative analysis. Results Sixty-six patients with minimal change disease, focal segmental glomerulosclerosis, IgA nephropathy, and membranous nephropathy responded to the survey, as well as 25 nephrologists from the NIH-funded Cure Glomerulonephropathy study network. Overall, patients performed fewer management tasks and acknowledged fewer informational needs than recommended by nephrologists. Patients were more knowledgeable about eHealth tools than nephrologists. Nine patient stakeholders reflected on the survey findings and noted a lack of awareness of key recommended management tasks and receiving little guidance from nephrologists on using eHealth. Key themes and concepts from the stakeholder meetings about eHealth tool development included the need for customizable design, trustworthy sources, seamless integration with other apps and clinical workflow, and reliable data tracking. The final design of our eHealth tool, the UrApp System, has 5 core features: “Profile” generates personalized data tracking, educational information, facilitation with provider discussions and inputting other preferences; “Data Tracking” displays patient health data with the ability to communicate important trends to patients and nephrologists; “Resources” provides trusted education information in a personalized manner; “Calendar” displays key events and generate reminders; and “Journal” facilitates information documentation using written or audio notes. Conclusion Our theory- and evidenced-based, stakeholder-engaged design process created designs for an eHealth tool to support the unique needs of patients with GN, optimized for effectiveness and implementation.
- 3 May 2024
- Published by S. Karger AG in Glomerular Diseases
- Vol. 4 (1) , 105-118
Open AccessDesign of a User-Centered Electronic Health Tool for Glomerular Disease Management
Introduction Patients with primary glomerular disease (GN) have unique management needs. We describe the design of a user-centered, patient-facing electronic health (eHealth) tool to support GN management. Methods We surveyed patients and GN expert nephrologists on disease management tasks, educational needs, and barriers and facilitators of eHealth tool use. Results were summarized and presented to patients, nephrologists, engineers, and a behavioral and implementation science expert in stakeholder meetings to jointly design an eHealth tool. Key themes from the meetings are described using rapid qualitative analysis. Results Sixty-six patients with minimal change disease, focal segmental glomerulosclerosis, IgA nephropathy, and membranous nephropathy responded to the survey, as well as 25 nephrologists from the NIH-funded Cure Glomerulonephropathy study network. Overall, patients performed fewer management tasks and acknowledged fewer informational needs than recommended by nephrologists. Patients were more knowledgeable about eHealth tools than nephrologists. Nine patient stakeholders reflected on the survey findings and noted a lack of awareness of key recommended management tasks and receiving little guidance from nephrologists on using eHealth. Key themes and concepts from the stakeholder meetings about eHealth tool development included the need for customizable design, trustworthy sources, seamless integration with other apps and clinical workflow, and reliable data tracking. The final design of our eHealth tool, the UrApp System, has 5 core features: “Profile” generates personalized data tracking, educational information, facilitation with provider discussions and inputting other preferences; “Data Tracking” displays patient health data with the ability to communicate important trends to patients and nephrologists; “Resources” provides trusted education information in a personalized manner; “Calendar” displays key events and generate reminders; and “Journal” facilitates information documentation using written or audio notes. Conclusion Our theory- and evidenced-based, stakeholder-engaged design process created designs for an eHealth tool to support the unique needs of patients with GN, optimized for effectiveness and implementation.
- Open Access
Improving Hepatitis B Screening Prior to Rituximab: A Quality Improvement Project
Rituximab, used in the treatment of some rheumatic and kidney diseases, can lead to hepatitis B virus (HBV) reactivation; HBV screening is recommended for those starting this medication. We aimed to improve by 50% the proportion of patients undergoing HBV screening by implementing multimodal interventions to support clinicians in this evidence-based practice. We conducted a quality improvement project from November 2020 to June 2022 at a tertiary care pediatric hospital system, including patients with rheumatic and/or kidney diseases starting rituximab. Multimodal interventions targeting clinicians included electronic health tools (dot phrase, display of screening recommendations and screening results in rituximab order sets/therapy plans), educational meetings, and e-mail/paper reminders. The primary outcome was the proportion of patients with complete HBV screening, while the secondary outcome was utilization of each laboratory component, tracked using statistical process control charts. Pre- and post-intervention data were compared using Fisher’s test. One hundred eighty-two patients who had been prescribed rituximab were included, of which 98 (54%) were post-intervention. The proportions of patients undergoing complete HBV screening (6% vs. 44%; p < 0.001), HBsAg collection (60% vs. 79%; p = 0.006), anti-HBsAb collection (14% vs. 54%; p < 0.001), and total anti-HBcAb collection (8% vs. 52%; p < 0.001) were significantly higher in the post-intervention period. Improvement was sustained over 18 months, with shifts and/or data points above the control limits in all measures. Forty-five patients were HBV-non-immune. In this study, multimodal interventions including electronic health tools and education of the provider significantly increased the proportion of patients screened for HBV prior to rituximab and identified immunization opportunities.
Open AccessImproving Hepatitis B Screening Prior to Rituximab: A Quality Improvement Project
Rituximab, used in the treatment of some rheumatic and kidney diseases, can lead to hepatitis B virus (HBV) reactivation; HBV screening is recommended for those starting this medication. We aimed to improve by 50% the proportion of patients undergoing HBV screening by implementing multimodal interventions to support clinicians in this evidence-based practice. We conducted a quality improvement project from November 2020 to June 2022 at a tertiary care pediatric hospital system, including patients with rheumatic and/or kidney diseases starting rituximab. Multimodal interventions targeting clinicians included electronic health tools (dot phrase, display of screening recommendations and screening results in rituximab order sets/therapy plans), educational meetings, and e-mail/paper reminders. The primary outcome was the proportion of patients with complete HBV screening, while the secondary outcome was utilization of each laboratory component, tracked using statistical process control charts. Pre- and post-intervention data were compared using Fisher’s test. One hundred eighty-two patients who had been prescribed rituximab were included, of which 98 (54%) were post-intervention. The proportions of patients undergoing complete HBV screening (6% vs. 44%; p < 0.001), HBsAg collection (60% vs. 79%; p = 0.006), anti-HBsAb collection (14% vs. 54%; p < 0.001), and total anti-HBcAb collection (8% vs. 52%; p < 0.001) were significantly higher in the post-intervention period. Improvement was sustained over 18 months, with shifts and/or data points above the control limits in all measures. Forty-five patients were HBV-non-immune. In this study, multimodal interventions including electronic health tools and education of the provider significantly increased the proportion of patients screened for HBV prior to rituximab and identified immunization opportunities.
- 21 June 2022
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 81 (1) , 25-35.e1
Vaccine Attitudes and COVID-19 Vaccine Intention Among Parents of Children With Kidney Disease or Primary Hypertension
- 21 June 2022
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 81 (1) , 25-35.e1
Vaccine Attitudes and COVID-19 Vaccine Intention Among Parents of Children With Kidney Disease or Primary Hypertension
- 18 November 2021
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (7) , 1585-1595
Determinants of medication adherence in childhood nephrotic syndrome and associations of adherence with clinical outcomes
Background Pediatric patients with nephrotic syndrome take medications long-term with significant toxicity and complex regimens, yet data on medication adherence are limited. Methods In a multicenter observational study of patients with nephrotic syndrome, NEPTUNE (NCT01209000), we surveyed caregivers of patients <19 years old and adolescent patients on medication adherence during longitudinal follow-up beginning in June 2015. Data extraction was in October 2020. We described the proportion of nonadherent patients at first survey. Participant social and economic factors, condition-related factors, therapy-related factors, and patient-related factors were examined for relationships with nonadherence by generalized linear mixed models using the longitudinal data. In exploratory fashion, we assessed the relationship between adherence and subsequent steroid response classification by binary logistic regression and adherence with healthcare utilization by Poisson regression. Results A total of 225 participants completed a median of 3 surveys during follow-up (IQR, 2–5), with a total of 743 surveys. Overall, 80 (36%) reported nonadherence with medications. In adjusted analysis, older age (per 1 year; OR 1.08; 95% CI, 1.03 1.12), lower maternal educational level (≥ high school vs. < high school; OR 0.47; 95% CI 0.25 to 0.89), and increased parent and self-identification of medications barriers (per 1 point; OR 1.57; 95% CI, 1.15–2.15) were significantly associated with nonadherence. No relationship between nonadherence and subsequent frequency of healthcare utilization was observed. A trend toward increased subsequent steroid resistance classification was seen with nonadherence, though not statistically significant. Conclusions Medication nonadherence is common in pediatric nephrotic syndrome. Investigations into the use of surveys in the clinic setting to identify at-risk patients and ways to support families over time are needed. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information.
- 18 November 2021
- Published by Springer Nature in Pediatric Nephrology
- Vol. 37 (7) , 1585-1595
Determinants of medication adherence in childhood nephrotic syndrome and associations of adherence with clinical outcomes
Background Pediatric patients with nephrotic syndrome take medications long-term with significant toxicity and complex regimens, yet data on medication adherence are limited. Methods In a multicenter observational study of patients with nephrotic syndrome, NEPTUNE (NCT01209000), we surveyed caregivers of patients <19 years old and adolescent patients on medication adherence during longitudinal follow-up beginning in June 2015. Data extraction was in October 2020. We described the proportion of nonadherent patients at first survey. Participant social and economic factors, condition-related factors, therapy-related factors, and patient-related factors were examined for relationships with nonadherence by generalized linear mixed models using the longitudinal data. In exploratory fashion, we assessed the relationship between adherence and subsequent steroid response classification by binary logistic regression and adherence with healthcare utilization by Poisson regression. Results A total of 225 participants completed a median of 3 surveys during follow-up (IQR, 2–5), with a total of 743 surveys. Overall, 80 (36%) reported nonadherence with medications. In adjusted analysis, older age (per 1 year; OR 1.08; 95% CI, 1.03 1.12), lower maternal educational level (≥ high school vs. < high school; OR 0.47; 95% CI 0.25 to 0.89), and increased parent and self-identification of medications barriers (per 1 point; OR 1.57; 95% CI, 1.15–2.15) were significantly associated with nonadherence. No relationship between nonadherence and subsequent frequency of healthcare utilization was observed. A trend toward increased subsequent steroid resistance classification was seen with nonadherence, though not statistically significant. Conclusions Medication nonadherence is common in pediatric nephrotic syndrome. Investigations into the use of surveys in the clinic setting to identify at-risk patients and ways to support families over time are needed. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information.